Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | CTSC | P53634 | 5/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7373996 | 1.00 | SMYD3 (0.43) | SMYD3CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL29044305 | 1.00 | SMYD3 (0.43) | SMYD3CHRNB2CHRNA4CHRNA7CHRNB4 | |
| Hydrochloric Acid SCHEMBL29044295 | 0.98 | SMYD3 (0.43) | SMYD3CHRNB2CHRNA4CHRNA7CHRNB4 | |
| Hydrochloric Acid SCHEMBL30537974 | 0.98 | SMYD3 (0.43) | SMYD3CHRNB2CHRNA4CHRNA7CHRNB4 | |
| Hydrochloric Acid SCHEMBL29044293 | 0.98 | SMYD3 (0.43) | SMYD3CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL16856366 | 0.82 | — | — | |
| SCHEMBL23833352 | 0.81 | SMYD3 (0.41) | SMYD3L3MBTL1DPP4DPP8DPP9 | |
| SCHEMBL1570045 | 0.80 | CTSK (0.40) | SMYD3CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL11770758 | 0.80 | SMYD3 (0.42) | SMYD3L3MBTL1DPP4DPP8DPP9 | |
| SCHEMBL24322630 | 0.79 | SMYD3 (0.43) | SMYD3L3MBTL1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507617-B | 1- (2- (4-Cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxypyrrolidine-2-carboxamide derivatives as VHL inhibitors | 基因泰克公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | GENENTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | GENENTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | GENENTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116507617-A | 1- (2- (4-cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxypyrrolidine-2-carboxamide derivatives as VHL inhibitors for the treatment of anaemia | 基因泰克公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022104345-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | GENENTECH, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-0243686-B1 | BETA-LACTAM COMPOUNDS, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-5093328-A | Carbapenicillin antibiotics | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0243686-A2 | Beta-lactam compounds, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | SMYD3 1777/4885CHRNB2 1867/4885CHRNA4 3643/4885 |
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | VHL, HIF1AN, FANCI | SMYD3 2310/4885CHRNB2 4866/4885CHRNA4 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.